

ASSESSING PATIENT-REPORTED OUTCOMES AND PHARMACIST INTERVENTIONS IN PATIENTS PRESCRIBED SPECIALTY MEDICATIONS FOR DERMATOLOGY AND ASTHMA, SINUS, AND ALLERGY

E. Danielle Bryan, PharmD¹ | Rebekah Finley, PharmD candidate² | Nisha B. Shah, PharmD¹ | Ryan Moore, MS³ | Josh DeClercq, MS³ | Leena Choi, PhD³ | Autumn D. Zuckerman, PharmD, BCPS, AAHVP, CSP¹
¹Vanderbilt Specialty Pharmacy, Vanderbilt University Medical Center; ²Lipscomb University College of Pharmacy; ³Department of Biostatistics, Vanderbilt University Medical Center

BACKGROUND

- Patient reported outcomes (PROs) can be used to assess therapeutic response and need for therapeutic changes in patients with dermatology, asthma, sinus, and allergy disease states.¹
- Vanderbilt Specialty Pharmacy, a health-system specialty pharmacy (HSSP), assesses PROs through monthly refill questionnaires (MRQs) to guide pharmacist interventions and improve patient care.²


OBJECTIVE

To assess PROs in patients receiving dermatology or asthma, sinus, and allergy (ASAP) medications at an HSSP

METHODS

- DESIGN** Single-center retrospective analysis
- INCLUSION** Patients receiving a dermatology or ASAP specialty medication with:
- 2+ fills through the center's specialty pharmacy, and
 - 2+ MRQ responses
- TIMEFRAME** January - March 2020

OUTCOMES




RESULTS

DERMATOLOGY COHORT (N=144)

TABLE 1. DERMATOLOGY PATIENT CHARACTERISTICS

	n (%)
Age, years, median (IQR)	53 (40-63)
Gender, male	61 (42)
Race	
White	114 (79)
Black or African American	22 (15)
Other Asian	4 (3)
Unknown	4 (3)
Insurance type	
Commercial	95 (66)
Medicare	44 (31)
Medicaid	4 (3)
Diagnosis	
Plaque psoriasis	92 (64)
Atopic dermatitis	31 (22)
Hidradenitis suppurativa	12 (8)
Mycosis fungoides	5 (3)
Other	4 (3)
Previous biologic therapy, yes	57 (40)

FIGURE 1. DERMATOLOGY MEDICATIONS



ASAP COHORT (N=46)

TABLE 2. ASAP PATIENT CHARACTERISTICS

	n (%)
Age, years, median (IQR)	50 (41-62)
Gender, male	19 (41)
Race	
White	31 (67)
Black or African American	14 (30)
Declined to answer	1 (2)
Insurance type	
Commercial	24 (52)
Medicare	18 (39)
Medicaid	4 (9)
Smoking status	
Non-smoker	30 (65)
Previous smoker	14 (30)
Current smoker	2 (4)
Previous biologic therapy, yes	27 (59)

FIGURE 2. ASAP DIAGNOSES AND MEDICATIONS






FIGURE 3. OVERALL MEDICATION EFFECTIVENESS



FIGURE 4. SPECIALTY PHARMACIST INTERVENTIONS FOR DERMATOLOGY AND ASAP PATIENTS (N=29)



CONCLUSIONS

- Patients with inflammatory conditions receiving care within an integrated health system specialty pharmacy reported high medication effectiveness with low rates of missed doses (3.2%) and adverse effects (<1%).
- Specialty pharmacists perform valuable interventions to ensure safe and effective medication use. Further research is needed to understand the long-term clinical outcomes in these populations.